UBE2D1

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, UBE2D1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UBE2D1 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher UBE2D1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2D1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, BLCA, and UCEC are the cancer types where UBE2D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
KIRCOSMedianAll0.2760.812<.00124view →
BLCAOSMedianAll0.1030.446.0476view →
UCECDFSMedianAll1.0000.635.0334view →
SKCMOSMedianAll0.4870.784.0433view →
Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UBE2D1–KIRC (OS)

Kaplan–Meier survival curve for UBE2D1 mutant vs wild-type samples in KIRC.

Open the KIRC breakdown →

Exploration